Su Q, Peng X, Zhou C X, Yu G Y
Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Feb 18;51(1):35-42. doi: 10.19723/j.issn.1671-167X.2019.01.007.
To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin.
Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated.
A total of 41 patients with primary parotid lymphoma were included in this retrospective study. The rate of male to female was 1:2.15. The median age was 57 years (ranging from 8 months to 91 years). According to WHO classification, 40 cases (97.1%) were diagnosed as non-Hodgkin lymphoma (NHL), including 15 cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), 14 cases of diffuse large B cell lymphoma (DLBCL) as well as 4 cases of follicular lymphoma, while other subtypes of NHL were rare. Only one case was diagnosed as Hodgkin lymphoma. Regarding the clinical staging at the initial diagnosis, 37 patients (90.2%) were diagnosed as stage IE or IIE of the disease, while 4 patients (9.8%) as stage IIIE or stage IVE. Seven patients (17.1%) had a history of Sjögren syndrome (SS), all of whom were MALT lymphoma. The mean ill duration of the 41 patients were 20.7 months. Thirty-two patients (78%) presented a slowly growing painless mass in the parotid gland. Treatment options included localized therapy and systemic therapy, all of whom had good curative effect. Nine patients (21.9%) died during the follow-up period. The overall survival rates of 2-year and 5-year were 84.5% and 81.3% respectively. The univariate analysis demonstrated statistically significant differences for accelerated growth of tumor (P=0.005), and presence of tumor capsule (P=0.011). The multi-univariate analysis demonstrated statistically significant differences for presence of tumor capsule (P=0.041).
A large majority of primary parotid lymphoma were NHL, among which MALT lymphoma and DLBCL were common subtypes. Most patients presented an indolent mass in parotid gland, which should be distinguished from the parotid benign tumors. SS is closely related to the pathogenesis of MALT lymphoma. The prognosis is better than that of other malignant parotid tumors. Absence of tumor capsule may predict a poor prognosis in patients with parotid lymphoma.
探讨腮腺原发性淋巴瘤的临床病理特征及预后因素。
回顾性收集并分析2006年至2016年在北京大学口腔医院初诊的腮腺淋巴瘤患者的临床病理资料。对患者进行5至149个月的随访,中位随访时间为45个月,并评估影响预后的因素。
本回顾性研究共纳入41例原发性腮腺淋巴瘤患者。男女比例为1:2.15。中位年龄为57岁(8个月至91岁)。根据世界卫生组织分类,40例(97.1%)被诊断为非霍奇金淋巴瘤(NHL),其中黏膜相关淋巴组织边缘区B细胞淋巴瘤(MALT)15例,弥漫性大B细胞淋巴瘤(DLBCL)14例,滤泡性淋巴瘤4例,其他NHL亚型少见。仅1例被诊断为霍奇金淋巴瘤。初诊时的临床分期方面,37例(90.2%)患者被诊断为疾病的IE期或IIE期,4例(9.8%)为IIIE期或IVE期。7例(17.1%)患者有干燥综合征(SS)病史,均为MALT淋巴瘤。41例患者的平均病程为20.7个月。32例(78%)患者表现为腮腺区缓慢生长的无痛性肿块。治疗方案包括局部治疗和全身治疗,所有患者疗效良好。9例(21.9%)患者在随访期间死亡。2年和5年总生存率分别为84.5%和81.3%。单因素分析显示肿瘤生长加速(P=0.005)和肿瘤包膜存在(P=0.011)有统计学显著差异。多因素分析显示肿瘤包膜存在(P=0.041)有统计学显著差异。
大多数原发性腮腺淋巴瘤为NHL,其中MALT淋巴瘤和DLBCL是常见亚型。大多数患者表现为腮腺区惰性肿块,应与腮腺良性肿瘤相鉴别。SS与MALT淋巴瘤的发病机制密切相关。其预后优于其他腮腺恶性肿瘤。无肿瘤包膜可能提示腮腺淋巴瘤患者预后不良。